Remarkable recent advances have revolutionized the field of heart failure. Survival has
improved among individuals with heart failure and a reduced ejection fraction and for the …

Episodes of worsening symptoms and signs characterize the clinical course of patients with
chronic heart failure (HF). These events are associated with poorer quality of life, increased …

Patients with heart failure with reduced ejection fraction (HFrEF) have a high residual risk of
adverse outcomes, even when treated with optimal guideline‐directed medical therapy and …

Aims Treatment response to vericiguat, based on baseline N‐terminal pro‐brain natriuretic
peptide (NT‐proBNP) subgroups specified in the protocol, was evaluated in the heart failure …

Abstract Purpose of Review The nitric oxide (NO)-soluble guanylate cyclase (sGC)-cyclic
guanosine monophosphate (cGMP) pathway plays an important role in the regulation of …

Despite recent advances in heart failure (HF) therapy, the risk of cardiovascular (CV)
mortality, morbidity, and HF hospitalization (HFH) are major challenges in HF treatment. We …

Background Acute heart failure (AHF) hospitalization presents an opportunity to optimize
pharmacotherapy to improve outcomes. Objectives This study's aim was to define eligibility …

Aims Patients who experience hospitalizations due to heart failure (HF) face a significant risk
of readmission and mortality. Our objective was to evaluate whether the risk of …

Worsening heart failure (HF) is a vulnerable period in which the patient has a markedly high
risk of death or HF hospitalization (up to 10% and 30%, respectively, within the first weeks …

Despite currently available treatments, risk of death and hospitalizations in patients with
heart failure with reduced ejection fraction (HFrEF) remains high. The pathophysiology of …